Discover Oculis' Annual General Meeting Invitation and Agenda

Author: Dylan Bailey Updated: 05-09-2025 04:17 PM

Oculis Invitation to the Annual General Meeting

Oculis Holding AG (NASDAQ: OCS / ICX: OCS.IC) has officially announced the invitation for its upcoming Annual General Meeting (AGM) scheduled for June 4, 2025. This pivotal event will be hosted at their Swiss headquarters, providing shareholders with the opportunity to engage directly with the company’s management team.

Details of the Meeting

The AGM will commence at 3:00 p.m. CEST, translating to 9:00 a.m. EDT. Attendees can expect both in-person participation and a live broadcast of the meeting, allowing for flexible involvement.

Joining the Meeting

For those looking to join the broadcast, Oculis has provided a straightforward link for access. In addition, they encourage participants to prepare by reviewing all related meeting materials, which can be found on the official Oculis website.

Virtual Information Session

In anticipation of the AGM, Oculis is hosting a virtual information session on May 19, 2025. This session will take place from 4:00 to 5:00 p.m. CEST (10:00 to 11:00 a.m. EDT) and will be available to all shareholders. During this session, company executives will present an overview of the meeting's proposals and welcome questions from shareholders.

Accessing the Information Session

Similar to the AGM, a dedicated link will be available for those who wish to participate in this informative session. After the event, the recorded webcast will be accessible on the Oculis website, providing a chance for shareholders unable to attend live to catch up.

About Oculis

Oculis is recognized as a pioneering global biopharmaceutical company, specializing in treatments for a variety of ophthalmic and neuro-ophthalmic conditions. With a commitment to addressing significant unmet medical needs, Oculis proudly presents a differentiated product pipeline in clinical development.

Innovative Product Candidates

Among its advancements, Oculis is developing OCS-01, a topical eye drop specifically aimed at treating diabetic macular edema (DME). Additionally, the company is working on Privosegtor (OCS-05), a neuroprotective candidate designed for acute optic neuritis, and Licaminlimab (OCS-02), targeting dry eye disease (DED) with a novel biologic anti-TNF? formulation. This strategic focus exemplifies Oculis' role in pushing the boundaries of treatment options for eye conditions.

Contact Information

For any inquiries related to the AGM or further information about Oculis, shareholders can reach out via the following contacts:

Oculis Contacts

Ms. Sylvia Cheung, CFO
Email: sylvia.cheung@oculis.com

Investor Relations

LifeSci Advisors
Corey Davis, Ph.D.
Email: cdavis@lifesciadvisors.com

Media Relations

ICR Healthcare
Amber Fennell / David Daley / Sean Leous
Email: oculis@icrhealthcare.com

Frequently Asked Questions

What is the date of Oculis' Annual General Meeting?

The AGM is scheduled for June 4, 2025.

How can I participate in the AGM?

Shareholders can attend in-person or join the live broadcast via the provided link.

Is there a virtual information session before the AGM?

Yes, Oculis will host a virtual information session on May 19, 2025, to discuss AGM proposals.

What innovative products is Oculis developing?

Oculis is working on several candidates including OCS-01 for diabetic macular edema and OCS-05 for optic neuritis.

Who can shareholders contact for more information?

Shareholders can contact Ms. Sylvia Cheung, CFO, or the investor relations team at LifeSci Advisors.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.